Literature DB >> 1845835

A murine cell line producing HTLV-I pseudotype virions carrying a selectable marker gene.

R G Vile1, T F Schulz, O F Danos, M K Collins, R A Weiss.   

Abstract

A murine cell line, EH, expressing the gag and pol proteins of Moloney murine leukemia virus (Mo-MLV) as well as an Mo-MLV recombinant genome with a selectable marker (histidinol dehydrogenase), was transfected with a plasmid coding for the gene of the human T-cell leukemia virus type I (HTLV-I) envelope precursor (gp62), placed under the control of the human cytomegalovirus immediate early promoter. One clone, T. 14, was recovered, in which gp62 RNA and protein were detected. Supernatant from this clone transferred the HisD gene to a panel of cell lines which express receptors for HTLV-I, but was unable to pass the marker gene to cells which do not express receptors. The colony-forming units were sensitive to HTLV-I receptor interference and to specific neutralization by anti-HTLV-I serum. These data show that hybrid virions were produced in which the envelope proteins of HTLV-I had pseudotyped Mo-MLV capside particles containing a selectable recombinant viral genome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845835     DOI: 10.1016/0042-6822(91)90050-l

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.

Authors:  J Arp; M LeVatte; J Rowe; S Perkins; E King; C Leystra-Lantz; S K Foung; G A Dekaban
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells.

Authors:  B S Schnierle; J Stitz; V Bosch; F Nocken; H Merget-Millitzer; M Engelstädter; R Kurth; B Groner; K Cichutek
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

3.  Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions.

Authors:  Kathryn S Jones; Manisha Nath; Cari Petrow-Sadowski; Andrea C Baines; Megan Dambach; Ying Huang; Francis W Ruscetti
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells.

Authors:  F Mammano; F Salvatori; S Indraccolo; A De Rossi; L Chieco-Bianchi; H G Göttlinger
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors.

Authors:  D Derse; S A Hill; P A Lloyd; B A Morse
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  TM domain swapping of murine leukemia virus and human T-cell leukemia virus envelopes confers different infectious abilities despite similar incorporation into virions.

Authors:  C Denesvre; C Carrington; A Corbin; Y Takeuchi; F L Cosset; T Schulz; M Sitbon; P Sonigo
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  A novel human T-leukemia virus type 1 cell-to-cell transmission assay permits definition of SU glycoprotein amino acids important for infectivity.

Authors:  L Delamarre; A R Rosenberg; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus.

Authors:  M Suomalainen; H Garoff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system.

Authors:  R E Sutton; D R Littman
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.